Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis

Peritoneal Dialysis International

Volumn 27, Issue SUPPL. 2, 2007, Pages

  García López, Elvia ^a   Carrero, Juan J ^a   Suliman, Mohamed E ^a   Lindholm, Bengt ^a   Stenvinkel, Peter ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiovascular disease; Homocysteine; Inflammation; Vascular calcification

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ATORVASTATIN; CALCIUM; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; GLUCOSE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICODEXTRIN; INTERLEUKIN 6; PERITONEAL DIALYSIS FLUID; PHOSPHATE BINDING AGENT; PYRIDOXINE; SEVELAMER; VITAMIN D RECEPTOR;

AGE DISTRIBUTION; ANEMIA; BLOOD PRESSURE REGULATION; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE EXACERBATION; DYSLIPIDEMIA; EPIGENETICS; HEART DISEASE; HEMODIALYSIS PATIENT; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASE; MINERAL DEFICIENCY; OXIDATIVE STRESS; PERITONEAL DIALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DIALYSIS SOLUTIONS; DISEASE PROGRESSION; DYSLIPIDEMIAS; HOMOCYSTINE; HUMANS; HYPERINSULINISM; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 35748937374     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (48)

1. Foley RN. Clinical epidemiology of cardiac disease in dialysis patients: left ventricular hypertrophy, ischemic heart disease, and cardiac failure. Semin Dial 2003; 16: 111-17.
2. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20:1048-56.
3. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9(Suppl 12):S16-23.
4. Massy ZA, Ivanovski O, Nguyen-Khoa T, Angulo J, Szumilak D, Mothu N, et al. Uremia accelerates both atheroscterosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 2005; 16:109-16.
5. Pecoits-Fitho R. The peritoneal cavity: a room with a view to the endothetium. Perit Dial Int 2005; 25:432-4.
6. Pernod G, Bosson JL, Golshayan D, Barro C, Forneris G, Martina G, et al. Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort. Kidney Int 2006; 69:1424-30.
7. Jungers P, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie M, Lacour B, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant 1997; 12:2597-602.
8. Atvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int Suppl 1997; 62:S48-52.
9. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003; 14(Suppl 4):S315-20.
10. Sattissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002; 39:283-90.
11. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-48.
12. Shen Y, Peake PW, Kelly JJ. Should we quantify insulin resistance in patients with renal disease? Nephrology (Carlton) 2005; 10:599-605.
13. Nishimura M, Murase M, Hashimoto T, Kobayashi H, Yamazaki S, Imai R, et al. Insulin resistance and impaired myocardial fatty acid metabolism in dialysis patients with normal coronary arteries. Kidney Int 2006; 69:553-9.
14. Mak RH. Insulin resistance in uremia: effect of dialysis modality. Pediatr Res 1996; 40:304-8.
15. Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2000; 15:65-70.
16. Amici G, Orrasch M, Da Rin G, Bocci C. Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2001; 17:80-3.
17. Kaysen GA, Don BR. Factors that affect albumin concentration in dialysis patients and their relationship to vascular disease. Kidney Int 2003; 63(Suppl 84):S94-7.
18. Pecoits-Filho R, Stenvinkel P, Wang AY, Heimbürger O, Lindholm B. Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int 2004; 24: 327-39.
19. Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, et al. Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2001; 12:814-21.
20. Ducloux D, Klein A, Kazory A, Devillard N, Chalopin JM. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int 2006; 69:331-5.
21. Stompor T, Krasniak A, Sulowicz W, Dembinska-Kiec A, Janda K, Wojcik K, et al. Changes in common carotid artery intima-media thickness over 1 year in patients on peritoneal dialysis. Nephrol Dial Transplant 2005; 20: 404-12.
22. Fine A. Relevance of C-reactive protein levels in peritoneal dialysis patients. Kidney Int 2002; 61:615-20.
23. Haubitz M, Brunkhorst R, Wrenger E, Froese P, Schulze M, Koch KM. Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy. Perit Dial Int 1996; 16:158-62.
24. Covic A, Goldsmith DJ, Florea L, Gusbeth-Tatomir P, Covic M. The influence of dialytic modality on arterial stiffness, pulse wave reflections, and vasomotor function. Perit Dial Int 2004; 24:365-72.
25. Carrero JJ, Axelsson J, Avesani CM, Heimbürger O, Lindholm B, Stenvinkel P. Being an inflamed peritoneal dialysis patient - a Dante's journey. Contrib Nephrol 2006; 150:144-51.
26. Zemel D, Krediet RT. Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: relationship to peritoneal permeability. Blood Purif 1996; 14:198-216.
27. Freeman LM, Roubenoff R. The nutrition implications of cardiac cachexia. Nutr Rev 1994; 52:340-7.
28. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353:1838-42.
29. Chung SH, Heimbürger O, Stenvinkel P, Wang T, Lindholm B. Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int 2003; 23:174-83.
30. Wang AY, Lai KN. The importance of residual renal function in dialysis patients. Kidney Int 2006; 69:1726-32.
31. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15:2186-94.
32. Wang AY, Lam CW, Wang M, Woo J, Chan IH, Lui SF, et al. Circulating soluble vascular cell adhesion molecule 1: relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am J Kidney Dis 2005; 45:715-29.
33. Chung SH, Heimbürger O, Stenvinkel P, Bergström J, Lindholm B. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 2001; 16:2240-5.
34. Suliman ME, Bárány P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P. Homocysteine in uraemia - a puzzling and conflicting story. Nephrol Dial Transplant 2005; 20:16-21.
35. Balakrishnan VS, Guo D, Rao M, Jaberm BL, Tighiouart H, Freeman RL, et al. Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. Kidney Int 2004; 65: 1449-60.
36. Losito A, Kalidas K, Santoni S, Jeffery S. Association of interteukin-6-174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 2003; 64:616-22.
37. Righetti M, Tommasi A, Lagona C, La Rosa L, Uccellini M, Sessa A. Effective homocysteine-lowering vitamin B treatment in peritoneal dialysis patients. Perit Dial Int 2004; 24:373-7.
38. Wei M, Esbaei K, Bargman J, Oreopoulos DG. Relationship between serum magnesium, parathyroid hormone, and vascular calcification in patients on dialysis: a literature review. Perit Dial Int 2006; 26:366-73.
39. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38:938-42.
40. Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, et al. Associations of serum fetuin-A with malnutrition, inflammation, atheroscterosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20:1676-85.
41. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62:245-52.
42. Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo J, Westenfetd R, et al. Sevelamer prevents uremia-enhanced atheroscterosis progression in apolipoprotein E-deficient mice. Circulation 2005; 112:2875-82.
43. Sharpies EJ, Varagunam M, Sinnott PJ, McCloskey DJ, Raftery MJ, Yaqoob MM. The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 2006; 26:64-8.
44. Akcay A, Ozdemir FN, Sezer S, Micozkadioglu H, Arat Z, Atac FB, et al. Association of vitamin D receptor gene polymorphisms with hypercalcemia in peritoneal dialysis patients. Perit Dial Int 2005; 25(Suppl 3):S52-5.
45. Akcay A, Micozkadioglu H, Atac FB, Agca E, Ozdemir FN. Relationship of eNOS and ras gene polymorphisms to initial peritoneal transport status in peritoneal dialysis patients. Nephron Clin Pract 2006; 104:c41-6.
46. Gillerot G, Goffin E, Michel C, Evenepoel P, Biesen WV, Tintillier M, et al. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 2005; 67:2477-87.
47. Dong C, Yoon W, Goldsmith-Clermont PJ. DNA methylation and atherosclerosis. J Nutr 2002; 132(Suppl 8): 2406S-9S.
48. Stenvinkel P, Karimi M, Johansson S, Axelsson J, Suliman M, Lindholm B, et al. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease? J Intern Med 2007; 261:488-99.